UNLABELLED: To avoid soreness and psychic stress following insulin injections by needle and syringe, the new jet injector DG-77 was used. It is a portable percutaneous pressure device with a spring, simple to operate which can be used to apply two different types of insulin. Thirty type 1 and type 2a diabetic patients participated in the study (10 females, 20 males). Insulin was applied using a needle and the DG-77 device in the same region of the body. A standardized questionnaire was compiled concerning simplicity of application, soreness, wish to possess the device and the possibility of acquiring it. The results obtained regarding the type of application were as follows: traditional way: glycemia: at 07(00)-8.5, 10(00)-10.5, 13(00)-7.4 mmol/l; insulinemia: at 07(00)-7.5, 10(00)-20.2, 13(00)-21.0 mU/l; jet injector: glycemia - at 07(00)-8.4, 10(00)-10.4, 13(00)-8.4 mmol/l; insulinemia: at 07(00)-2.8, 10(00)-12.3, 13(00)-20.0 mU/l, which was not statistically significant; for glycemia: at 10(00), t = 0.110, p greater than 0.05, at 13(00), t = 1.88, p greater than 0.05, and for insulinemia at 10(00), t = 0.82, p greater than 0.05, and at 13(00), t = 1.23, p greater than 0.05. IN CONCLUSION: 1) blood glucose and insulin control with the jet injector administration of insulin was equally successful as with the standard insulin application; 2) incidence of hematoma was not significant; 3) eighty-five percent of patients prefer the injector due to its simplicity of application, reduced soreness and would wish to possess the device.
UNLABELLED: To avoid soreness and psychic stress following insulin injections by needle and syringe, the new jet injector DG-77 was used. It is a portable percutaneous pressure device with a spring, simple to operate which can be used to apply two different types of insulin. Thirty type 1 and type 2a diabeticpatients participated in the study (10 females, 20 males). Insulin was applied using a needle and the DG-77 device in the same region of the body. A standardized questionnaire was compiled concerning simplicity of application, soreness, wish to possess the device and the possibility of acquiring it. The results obtained regarding the type of application were as follows: traditional way: glycemia: at 07(00)-8.5, 10(00)-10.5, 13(00)-7.4 mmol/l; insulinemia: at 07(00)-7.5, 10(00)-20.2, 13(00)-21.0 mU/l; jet injector: glycemia - at 07(00)-8.4, 10(00)-10.4, 13(00)-8.4 mmol/l; insulinemia: at 07(00)-2.8, 10(00)-12.3, 13(00)-20.0 mU/l, which was not statistically significant; for glycemia: at 10(00), t = 0.110, p greater than 0.05, at 13(00), t = 1.88, p greater than 0.05, and for insulinemia at 10(00), t = 0.82, p greater than 0.05, and at 13(00), t = 1.23, p greater than 0.05. IN CONCLUSION: 1) blood glucose and insulin control with the jet injector administration of insulin was equally successful as with the standard insulin application; 2) incidence of hematoma was not significant; 3) eighty-five percent of patients prefer the injector due to its simplicity of application, reduced soreness and would wish to possess the device.